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a sex ratio (M/F) of 2.05. The majority (80.3%) of them 
was 50 years or older, while the proportion of subjects 
younger than 30 years of age was as low as 3.3%. No dif-
ference was detected by geographical area of residence. 
The presence of liver cirrhosis was diagnosed in 52.4% 
of cases. In comparison to previous studies, a further shift 
towards the oldest age groups and an increasing proportion 
of subjects having liver cirrhosis among all anti-delta-posi-
tive subjects are observed.
Conclusions Currently, hepatitis delta infection mostly 
affects old people who have an advanced but indolent liver 
disease, reflecting a survival effect. The defective hepatitis 
delta virus is near to disappear in the country, where it has 
been discovered in the second half of 70s.
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HDV  Hepatitis delta virus
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HBsAg  Hepatitis B surface antigen
anti-HDV  Antibodies to delta virus
HCC  Hepatocellular carcinoma
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Introduction
Hepatitis delta virus (HDV) discovered in the 1970s [1, 2] 
is a defective RNA virus requiring the helper function of 
hepatitis B virus (HBV) to establish its own infection. This 
discovery opened a new window for the knowledge of liver 
diseases adding important new issues even to the natural 
history of HBV infection. At that time, HDV was endemic 
Abstract 
Background The endemicity of hepatitis delta virus infec-
tion in Italy has decreased in the last decades.
Aim To evaluate the current epidemiology of chronic delta 
infection in Italy and to compare the present findings with 
the corresponding figures from the previous studies.
Methods A cross-sectional study involving 16 referral cen-
tres scattered all over the country in 2014.
Results Out of the 513 hepatitis B surface antigen-positive 
subjects enrolled, 61 (11.9%) were anti-delta positive, with 
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in Italy, particularly in Southern areas, accounting for the 
majority of cases of juvenile cirrhosis [3]. High prevalence 
rates of HDV infection were worldwide reported, espe-
cially in Mediterranean areas, Eastern Europe, the Amazon 
basin and central Asia [4].
In Italy, after the introduction of the mass immunization 
campaign against HBV in 1991 for 3-month-old infants 
and for subjects of 12 years of age (the latter limited to the 
first 12 years of campaign), a control even of HDV infec-
tion was expected. In fact, since the second half of 80s the 
incidence rate of acute HDV per million of inhabitants pro-
gressively declined from 3.1 cases in 1987 to 0.5 cases in 
2004 [5, 6]. The downward trend was mostly affecting the 
15–24 years old age group, both reflected the decreased 
pool of chronic hepatitis B surface antigen (HBsAg) car-
riers [7], and the impact of mass immunization campaign 
against HBV.
Similarly, the prevalence of antibodies to delta virus 
(anti-HDV) evaluated among cohorts of chronic HBsAg 
carriers referring Italian hospitals progressively declined 
over time, being 23.4% in 1987 [8], 14.0% in 1992 [9], 
8.3% in 1997 [10], 5.7% in 2001 [11], and 8.1% in 2006 
[12], respectively.
In this paper, we report the results of a further national 
survey performed in 2014 on the epidemiology of chronic 
HDV infection in Italy. Moreover, the present findings have 
been compared with the corresponding figures from the 
previous studies [8–12] to detect changes, if any.
Materials and methods
All HBsAg-positive subjects consecutively referring 
in 2014, as either inpatients or outpatients, to 16 Liver 
Units were recruited. Patients with acute B hepatitis were 
excluded from the study. The Liver Units participating 
were located throughout the country.
Liver cirrhosis was diagnosed by liver biopsy or on the 
presence of the characteristics of clinical, biochemical 
and ultrasound signs [13]. The diagnosis of hepatocellular 
carcinoma (HCC) was based on histological and/or imag-
ing findings and on serum alpha-fetoprotein (AFP) levels, 
according to accepted criteria [14].
The collection of personal data was made in full compli-
ance with the Italian law on personal data collection, and 
each patient gave his/her informed consent to participate. 
All procedures applied in the study were in accordance with 
the international guidelines, with the standards of human 
experimentation of the local Ethics Committees, and with 
the Helsinki Declaration of 1975, revised in 1983. Each 
patient signed informed consent for the collection of per-
sonal data, established in full agreement with the rules of 
the Ethic Committee of the coordinating centre (A.O.U.P. 
of Palermo, Italy). Patients who agreed to undergo liver 
biopsy signed informed consent before this procedure was 
performed. All patients were included only once, i.e. at the 
first observation during the study period. For each patient, 
demographic, clinical, and etiological data were recorded 
using e pre-coded questionnaire (Air-Tel telematica, Italy).
HBV serum markers and antibodies to hepatitis D virus 
(anti-HDV) were determined by commercial immunoenzy-
matic assays.
Statistical analysis
Categorical variables were summarized as absolute counts 
and proportions. Differences in proportion were evaluated 
by Chi square test or Fisher’s exact test. A p value <0.05 
was considered to be significant. Crude odds ratios (ORs) 
for the association of anti-HDV positivity with different 
variables were calculated by univariate analysis. The ref-
erence category for ORs estimates was no exposure or the 
most favourable level of exposure.
Results
During the study period, 513 chronic HBsAg carriers were 
enrolled. All were tested for anti-HDV. Among them, 61 
(11.9%) had an anti-HDV-positive test result, a figure 
slightly higher than those reported in the studies performed 
since the year 1997 (Fig. 1). The main characteristics of 
the 61 anti-HDV-positive subjects are reported in Table 1. 
Sex ratio (male/female) was 2.05, and the majority (80.3%) 
of subjects were 50 years or older, while the proportion of 
subjects younger than 30 years of age was as low as 3.3%. 
Twelve (19.7%) of these 61 were anti-HCV positive. Liver 
biopsy was performed in 24.6% of cases, liver cirrhosis 
was diagnosed in 32 subjects (52.4%) and in three of them 
HCC was detected.
Fig. 1  Prevalence of anti-HDV positivity among chronic HBsAg car-
riers in Italy over time
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The age-distribution of anti-HDV-positive subjects in 
Italy over time plotted in Fig. 2 provides interesting infor-
mation. During the period 1987–2014, the proportion of 
cases in the age group of 0–29 and 30–49 years strongly 
decreased from 39.8 to 3.3% and from 50.6 to 16.4%, 
respectively. In contrast, the proportion of cases in sub-
jects with 50 years or older increased from 9.6 to 80.3% 
(Table 2).
Anti-HDV prevalence was slightly higher in Northern/
Centre than Southern/Islands areas (13.6 vs. 12.0%), a find-
ing completely different from that observed in the previous 
surveys, which have shown a much higher prevalence than 
the latter regions.
Table 3 reports the sociodemographic characteristics of 
anti-HDV-positive subjects, the potential risk factors and 
the crude ORs with their 95% Confidence Intervals (CI) 
derived from univariate analysis. The presence of cirrho-
sis resulted the sole variable significantly associated with 
HDV infection (OR 2.6, 95% CI 1.5–4.5). Since only one 
variable resulted associated, multiple logistic regression 
was not performed. Finally, the proportion of subjects with 
anti-HDV-positive patients with liver cirrhosis increased 
from 35.7% in 1987 to 52.4% in 2014 (p < 0.05) (Table 4).
Discussion
The data herein reported complete the picture of chronic 
HDV infection in Italy over a very long period (1987–
2014). Since several units participating in the current 
survey took also part in all previous investigations, cur-
rent findings are suitable to be compared with the pre-
vious ones. Despite the current anti-HDV prevalence is 
slightly higher than that observed in the previous study 
performed in 2006 (11.9 vs. 8.1%), we may assert that the 
spread of HDV infection in Italy is vanishing. Some lines 
of evidence support this evidence. Firstly, the age distri-
bution of cases is mostly confined to people with more 
than 50 years of age, whilst people younger than 30 years 
account for only 3.3% of cases, Secondly, the proportion of 
Table 1  Study population of 61 anti-HDV-positive subjects
a
 Three subjects with hepatocellular carcinoma
Characteristic No (%)
Anti-HDV prevalence (HDV+/HBsAg+) 61/513 (11.9)
Sex ratio (M/F) 41/20 (2.05)
Age-distribution (years)
 0–29 2 (3.3)
 20–49 10 (16.4)
 >49 49 (80.3)
Liver biopsy 15 (24.6)
Presence of cirrhosisa 32 (52.4)
Fig. 2  Age distribution of anti-
HDV-positive subjects in HBs 
Ag carriers in Italy from 1987 
to 2014
Table 2  Prevalence of anti-HDV positivity among chronic HBsAg 
carriers in Italy by geographical area, over time (1987–2014)
Year Percent of patients with anti-HDV positivity among 
chronic HBsAg carriers
North/Centre (%) South/Islands (%) References
1987 13.1 26.6 [7]
1992 9.0 18.5 [8]
1997 1.9 11.3 [9]
2001 6.6 8.3 [10]
2006 8.7 6.7 [11]
2014 13.6 12.0 Present study
280 T. Stroffolini et al.
1 3
cirrhotic patients among all HDV-infected subjects has sig-
nificantly increased over time reaching the current rate of 
52.4%, likely reflecting a so-called “survival effect”. Taken 
together, these findings evidence a low current spread of 
HDV infection with an accumulation of cases having an 
advanced, slowly evolving disease. Actually, HDV infec-
tion in Italy is an ageing disease with a long-term survival, 
which explains the observed slightly higher overall anti-
HDV prevalence observed in the present study as compared 
to previous ones. This is in agreement with a follow-up 
study of subjects with biopsy-proven chronic HDV infec-
tion in two Italian medical centres showing a stable clinical 
cirrhosis for more than a decade [15].
The low proportion of cases in people younger than 
30 years is an expected finding due to the mass vaccina-
tion campaign against HBV started in 1991, which depleted 
in the youngest age group the HBsAg carrier reservoir that 
represents the necessary substrate for the replication of HDV 
defective virus [16]. A second effect to explain the decline in 
HBV endemicity is the successful treatment of HBV infection 
with nucleoside analogues or other drugs with low adverse 
events since 1998. Indeed, this treatment has been extensively 
administered in Italy in the latter 15 years, but in the absence 
of a national register we may not be accurate on this point.
For several years, HDV infection has been character-
ized by a higher prevalence in Southern than in Northern 
Italian areas [8–11]. However, since the survey of 2006 
[12], the prevalence has become higher in the latter ones. 
This evolving geographical pattern may reflect changes 
in the modes of transmission. Intrafamilial spread was the 
main source of HDV infection in Southern areas, whereas 
illicit drug abuse was the predominant risk factor in North-
ern Italy [8, 10, 17]. The reduced family size even in the 
South has affected the spread of infection in these areas, 
while i.v. drug use has continued to be practised, particu-
larly in Northern areas, where it has been responsible for 
some epidemic peaks [6]. Although the majority of HDV-
infected subjects have liver cirrhosis, its contribution to the 
entire pool of cirrhosis in Italy should be considered mini-
mal. The last published survey [18] has shown that 13% of 
cirrhosis are HBV related and nearly 20% of these cirrho-
sis are caused by simultaneous HDV infection. Therefore, 
a little more than 2.5% of all cirrhosis cases in Italy are 
attributable to HDV infection.
Table 3  Prevalence 
of anti-HDV positivity 
by sociodemographic 
characteristics and potential risk 
factors in 513 HBsAg-positive 
subjects, 2014
Crude odds ratio (OR) derived by univariate analysis
IVDU intravenous drug use
Characteristic HBsAg-positive No of cases Anti-HDV-positive % of cases OR (95% CI)
Sex
 Females 183 10.9 1
 Males 330 12.4 1.2 (0.7–1.5)
Age (years)
 0–29 15 13.3 1
 30–49 126 7.9 0.6 (0.1–2.8)
 >49 371 13.2 0.99 (0.2–4.5)
Area of residence
 North/Centre 103 13.6 1.2 (0.6–2.2)
 South/Islands 375 12.0 1
Country of birth
 Italy 478 12.3 2.3 (0.5–9.9)
 Outside Italy 35 5.7 1
Educational level
 High 113 11.5 1
 Medium–Low 400 12.0 0.7 (0.4–1.6)
Blood transfusion 51 11.8 0.99 (0.4–2.4)
IVDU 32 9.4 1.3 (0.4–4.5)
Presence of cirrhosis 166 19.3 2.6 (1.5–4.5)
Table 4  Proportion of subjects with liver cirrhosis among anti-HDV 
positive in Italy (1987–2014)
Year Presence of cirrhosis No (%) References
1987 130/364 (35.7%) [7]
1992 61/143 (42.6%) [8]
1997 30/69 (43.5%) [9]
2001 43/104 (41.4%) [10]
2006 37/95 (38.9%) [11]
2014 32/61 (52.4%) Present study
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The decreasing endemicity of HDV infection in Italy has 
led to a downgrading alert about the risk of its spreading. 
In fact, it has been shown that 35.3% of HBsAg-positive 
subjects in Southern Italy in 2005 [19], and as many as 
53.8% of acute HBV cases during the period 1993–2004 
[6] were not tested for anti-HDV. More attention should be 
addressed to HDV infection testing for all subjects who are 
found to be HBsAg positive.
In conclusion, current HDV infection in Italy mostly 
affects old people who have an advanced but indolent liver 
disease, as a consequence of survival effect. Based on this 
epidemiological survey, we can hypothesize that this defec-
tive virus is near to disappear in the Country where it has 
been firstly discovered in the second half of 70s.
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